X
OCUL icon

Xponance’s Ocular Therapeutix OCUL Stock Holding History

Xponance’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$194K Buy
19,745
+2,638
+15% +$23.9K ﹤0.01% 1617
2026
Q1 		$145K Buy
17,107
+2,473
+17% +$23.6K ﹤0.01% 1524
2025
Q4 		$178K Buy
14,634
+3,679
+34% +$44.7K ﹤0.01% 1409
2025
Q3 		$128K Buy
10,955
+89
+0.8% +$1.06K ﹤0.01% 1419
2025
Q2 		$101K Sell
10,866
-969
-8% -$7.58K ﹤0.01% 1410
2025
Q1 		$86.8K Buy
11,835
+754
+7% +$5.79K ﹤0.01% 1361
2024
Q4 		$94.6K Buy
11,081
+812
+8% +$7.92K ﹤0.01% 1372
2024
Q3 		$89.3K Buy
+10,269
New +$84.6K ﹤0.01% 1327

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Xponance's OCUL Position: Q2 2026 in Review

Xponance increased its Ocular Therapeutix (OCUL) stake by 15% in Q2 2026, buying an estimated $23.9K and bringing the position to 19,745 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #1617.

Xponance first reported a position in OCUL in Q3 2024 and has held it in 8 quarters since. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Xponance held 19,745 shares of Ocular Therapeutix worth $194K as of Q2 2026.
  • Xponance bought 2,638 Ocular Therapeutix shares in Q2 2026, an estimated $23.9K.
  • Ocular Therapeutix made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1617 holding.
  • Xponance first reported a position in Ocular Therapeutix in Q3 2024 and has held it in 8 quarters since.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.